This system has failed you... Now it can pay you

American medicine is just as rotten and corrupt as American finance. [The Wiggin Sessions]( October 25, 2022 [UNSUBSCRIBE]( A Note From Addison: I am handing over this morning’s missive to Dr. David Eifrig and his team at Stansberry Research. We have worked with Stansberry Research for a long time. We appreciate the effort Dr. Eifrig and his team put into their business at Stansberry Research and would not put their message in The Wiggin Sessions if we did not support their work. This system has failed you… Now it can pay you Dear Reader, More than twenty years ago, I left a lucrative career on Wall Street to study medicine. [Click here to learn more]( I became an eye surgeon. I soon learned that [American medicine is just as rotten and corrupt as American finance](. So I left medicine too, and started a third career, writing about stocks... and helping ordinary folks learn how to retire wealthy and worry-free. Believe me, I know how badly these systems have failed you. How much aggravation they've probably caused. [But if you've ever wanted to stick it to either one of them – you urgently need to see this.]( It's a huge development I've waited 40 years for… Creating the biggest money-making opportunity I've ever seen in my life. And it's happening while everyone is distracted by the crashing market. I'm telling you, as a physician, medical researcher, MBA, and market analyst for decades, [it's time to pay attention to this one inflation-and recession-resistant sector](. Health and medicine are undergoing a radical transformation. Trillions are changing hands. And the COVID-19 crisis put this transformation on steroids. The research firm Forrester reported that health care “accelerated by a decade in a matter of months.” And the CEO of Johnson & Johnson just went on record predicting that "the next 10 years will bring greater medical innovation than the last 100 years combined." When [you've seen this...]( I guarantee you'll never look at the health care system... your own health decisions... or your investing dollars.... the same way ever again. This information could lead you to a series of triple-digit gains... maybe even save your life or the life of someone you love. [That's why I'm sharing the most important research of my life, completely for free, at this private link](. Here's to our health, wealth, and a great retirement, Dr. David Eifrig, MD, MBA Senior Partner, Stansberry Research --------------------------------------------------------------- Ed. note: Got something to say? Send your feedback to The Wiggin Sessions [here](mailto:WigginSessions@5minforecast.com). LISTEN ON [The Wiggin Sessions]( The Wiggin Sessions is committed to protecting and respecting your privacy. We do not rent or share your email address. By submitting your email address, you consent to Consilience, LLC. delivering daily email issues and advertisements. To end your The Wiggin Sessions e-mail subscription and associated external offers sent from The Wiggin Sessions, feel free to [click here.]( Please read our [Privacy Statement.]( For any further comments or concerns please email us at support@5minforecast.com. If you are having trouble receiving your The Wiggin Sessions subscription, you can ensure its arrival in your mailbox by [whitelisting The Wiggin Sessions.]( © 2022 Consilience, LLC. 808 Saint Paul Street, Baltimore MD 21202. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security they personally recommend to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.